Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stuart Soroka

Gastroenterology St Augustine, FL Medical Doctor

NPI 1922069707 CMS profile 87493

216 Southpark Cir E, St Augustine, FL 32086

Open in the dashboard

General payments

$8,386

494 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stuart Soroka of St Augustine, FL is reported in the CMS Open Payments database as having received $8,386 across 494 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,871 102
2024 General $1,607 88
2023 General $2,068 129
2022 General $1,262 73
2021 General $843 50
2020 General $202 13
2019 General $534 39

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stuart Soroka
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Stuart Soroka were reported at $1,871. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Stuart Soroka Gastroenterology median Middle half National median
2019 $534 $417 $126–$1,100 $163
2020 $202 $224 $74–$624 $114
2021 $843 $352 $106–$1,054 $132
2022 $1,262 $448 $129–$1,270 $149
2023 $2,068 $533 $150–$1,390 $160
2024 $1,607 $605 $160–$1,606 $164
2025 $1,871 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,300 146 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $1,047 62 payments
  3. Janssen Biotech, Inc. $795 50 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $736 44 payments
  5. Genzyme Corporation $481 22 payments
  6. Merck Sharp & Dohme Corporation $360 22 payments
  7. Celgene Corporation $295 21 payments
  8. Regeneron Healthcare Solutions, Inc. $264 13 payments
  9. Madrigal Pharmaceuticals $251 14 payments
  10. Pfizer Inc. $230 15 payments
  11. Other $1,627 85 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,368 493 payments
  2. Education $18 1 payment
Products named General payments · program years 2019–2025
  1. ENTYVIO $834 46 payments
  2. XIFAXAN $642 38 payments
  3. CREON $634 46 payments
  4. LINZESS $631 45 payments
  5. RINVOQ $620 33 payments
  6. SKYRIZI $512 29 payments
  7. STELARA $500 31 payments
  8. DUPIXENT $481 22 payments
  9. HUMIRA $407 25 payments
  10. DIFICID $360 22 payments
  11. Other $4,093 244 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,273

Median for Gastroenterology: 569

Drug cost

$453,130

Median for Gastroenterology: $104,976

Branded share of claims

20.5%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ocaliva Obeticholic Acid Brand 15 $235,615
Simponi Golimumab Brand 12 $82,089
Linzess Linaclotide Brand 66 $54,549
Mesalamine Generic 38 $20,616
Erythromycin Erythromycin Base Brand 27 $8,253
Ursodiol Generic 28 $7,770
Omeprazole Generic 414 $7,404
Trulance Plecanatide Brand 11 $6,965
Budesonide Dr Budesonide Brand 30 $4,822
Balsalazide Disodium Generic 21 $3,826

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$189,129

Medicare's payments for the services billed

Medicare patients

667

Average age 75

Services billed

3,142

367 women, 300 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Ischemic heart disease 43%
Chronic kidney disease 31%
Diabetes 30%
Atrial fibrillation 23%
Depression 23%
COPD 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $220
$220 — —
Sucraid
  • QOL Medical, LLC $155
$155 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $154
$154 — —
DUPIXENT
  • GENZYME CORPORATION $100
  • Regeneron Healthcare Solutions, Inc. $35
$135 — —
RINVOQ
  • AbbVie, Inc. $99
$99 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

494 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record